- Conditions
- Acute Myocardial Infarction, Unstable Angina
- Interventions
- Therapeutic ultrasound with 20 usec
- Procedure
- Lead sponsor
- University of Sao Paulo General Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- CoreAalst BV
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 888 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Stanford, California • Decatur, Georgia • Bangor, Maine
- Conditions
- AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 19
- States / cities
- La Jolla, California • San Francisco, California • Miami, Florida + 12 more
- Conditions
- Non-ST Elevation Acute Coronary Syndrome
- Interventions
- ticagrelor, clopidogrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
- Conditions
- Acute Anterior Myocardial Infarction
- Interventions
- Abciximab local infusion, No local infusion, Thrombus aspiration
- Drug · Other · Procedure
- Lead sponsor
- Atrium Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 7
- States / cities
- Takoma Park, Maryland • Charlotte, North Carolina • Greensboro, North Carolina + 4 more
- Conditions
- Acute Myocardial Infarction, Coronary Artery Disease
- Interventions
- Physiology-guided NCL PCI, Angiography-guided NCL PCI
- Procedure
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Wichita, Kansas + 9 more
- Conditions
- Lung Cancer
- Interventions
- Prophylactic Cranial Irradiation, Radiation Therapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 108
- States / cities
- Tucson, Arizona • Fresno, California • Sacramento, California + 87 more
- Conditions
- Coronary Artery Disease, Myocardial Infarction
- Interventions
- Lithotripsy
- Device
- Lead sponsor
- Shockwave Medical, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • La Jolla, California • Orange, California + 32 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- BMN 349, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- San Diego, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Graft Versus Host Disease (GVHD)
- Interventions
- Alpha-1 antitrypsin (AAT), Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome
- Interventions
- BrightHeart®
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Saphenous Vein Graft Atherosclerosis
- Interventions
- Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
- Device · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more
- Conditions
- Anterior Acute Myocardial Infarction (AMI)
- Interventions
- Supersaturated O2 Therapy of the Therox Downstream System®, PCI alone
- Device · Procedure
- Lead sponsor
- TherOx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Charleston, West Virginia • Huntington, West Virginia
- Conditions
- Acute Myocardial Infarction
- Interventions
- Acetaminophen, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Coronary Syndrome
- Interventions
- Milvexian, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 162
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more
- Conditions
- Coronary Disease
- Interventions
- Placebo Oral Tablet, Atorvastatin 80mg, Screening
- Drug · Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease
- Interventions
- OCT-NIRAF, LUMISIGHT Injection, OCT-NIRAF following LUMISIGHT Injection
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ST Elevation Myocardial Infarction, Cardiovascular Diseases
- Interventions
- No intervention, Interview, Survey
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Coronary Artery Disease
- Interventions
- FFRangio
- Device
- Lead sponsor
- CathWorks Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Stanford, California • New York, New York • Roslyn, New York + 1 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- INO-1001
- Drug
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 10
- States / cities
- Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Interventions
- Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 65 Years and older
- Enrollment
- 547 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 917
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 596 more
- Conditions
- Coronary Artery Disease
- Interventions
- AI-enabled quantitative coronary plaque analysis (AI-QCPA)
- Diagnostic Test
- Lead sponsor
- HeartFlow, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Greensboro, North Carolina